Janssen CarePath provides support services for patients prescribed Xarelto (rivaroxaban), a medication used to prevent blood clots and reduce the risk of stroke and systemic embolism in certain patients with atrial fibrillation [1]. The program aims to help eligible patients access and afford their Xarelto prescription [1].
What does Janssen CarePath offer for Xarelto patients?
The Janssen CarePath program assists patients by offering co-pay savings cards for commercially insured individuals, helping to lower out-of-pocket costs for Xarelto. For uninsured or underinsured patients, it may provide assistance through the Janssen Pharmaceutical Companies of Johnson & Johnson Patient Assistance Foundation [1]. The program also offers services such as refill reminders and prescription status tracking to help patients stay on track with their treatment [1].
How do I enroll in Janssen CarePath for Xarelto?
Enrollment in Janssen CarePath typically involves speaking with a healthcare provider. Patients can obtain a co-pay savings card or discuss other assistance options through their doctor's office or by contacting Janssen CarePath directly for guidance on eligibility and the enrollment process [1]. Information is available on the Janssen CarePath website.
How much does Xarelto cost and is there financial assistance available?
The cost of Xarelto can vary depending on insurance coverage and dosage. For patients with commercial insurance, Janssen CarePath offers a co-pay savings program that can reduce out-of-pocket expenses to as little as $10 per prescription for up to 24 months [1]. For those who are uninsured or underinsured, the Janssen Pharmaceutical Companies of Johnson & Johnson Patient Assistance Foundation may provide free medication to eligible individuals [1].
What is Xarelto and what is it used for?
Xarelto is a brand name for rivaroxaban, an anticoagulant, commonly known as a blood thinner [2]. It works by inhibiting Factor Xa, a key component in the blood clotting cascade [2]. Xarelto is prescribed to:
* Prevent stroke and reduce the risk of systemic embolism in non-valvular atrial fibrillation [2].
* Treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
* Reduce the risk of recurrent DVT and PE [2].
* Prevent DVT and PE in certain patients who have undergone hip or knee replacement surgery [2].
When does the patent for Xarelto expire?
The patent landscape for Xarelto is complex and involves multiple patents covering different aspects of the drug, including its composition, manufacturing processes, and methods of use. While specific patent expiry dates can be found on specialized patent databases, patents for blockbuster drugs like Xarelto are often subject to extensions and legal challenges. For detailed information on Xarelto's patent status and expiry timelines, resources like DrugPatentWatch.com can provide comprehensive data [3].
Who are Xarelto's competitors and when might generic versions be available?
Xarelto is a direct oral anticoagulant (DOAC) and competes with other DOACs such as Eliquis (apixaban), Pradaxa (dabigatran), and Savaysa (edoxaban) [2]. The availability of generic versions of Xarelto is dependent on the expiry of its patents and any associated market exclusivity periods. Once patents expire and exclusivity ends, generic manufacturers can seek approval to market their versions of rivaroxaban, which would likely lead to lower prices.
Sources:
[1] Janssen CarePath. https://www.janssencarepath.com/
[2] Xarelto Prescribing Information. https://www.janssenlabels.com/xarelto/prescribing-information.pdf
[3] DrugPatentWatch.com. https://www.drugpatentwatch.com/